Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.57 |
| ▸ | EGFR | P00533 | 6/20 | 0.54 |
| ▸ | ABL1 | P00519 | 5/20 | 0.54 |
| ▸ | CDK1 | P06493 | 3/20 | 0.54 |
| ▸ | PRKCA | P17252 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | ABL2 | P42684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8129590 | 0.99 | SRC (0.58) | SRCEGFRABL1CDK1PRKCA | |
| SCHEMBL13064037 | 0.93 | EGFR (0.53) | SRCEGFRABL1CDK1PRKCA | |
| SCHEMBL13064030 | 0.93 | MAPT (0.62) | SRCEGFRABL1CDK1PRKCA | |
| SCHEMBL8121867 | 0.93 | MAPT (0.62) | SRCEGFRABL1CDK1PRKCA | |
| SCHEMBL8122075 | 0.93 | EGFR (0.53) | SRCEGFRABL1CDK1PRKCA | |
| SCHEMBL8125505 | 0.92 | SRC (0.55) | SRCEGFRABL1CDK1PRKCA | |
| SCHEMBL6185651 | 0.91 | SRC (0.53) | SRCEGFRABL1CDK1PRKCA | |
| SCHEMBL8129918 | 0.91 | KDM4E (0.54) | ABL1KDM4EPRMT5ALDH1A1MAPT | |
| SCHEMBL8121978 | 0.89 | SRC (0.53) | SRCEGFRABL1CDK1PRKCA | |
| SCHEMBL8121850 | 0.85 | PRMT5 (0.48) | SRCEGFRABL1CDK1PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-0819129-B1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2000-08-02 | — | — | EP | disclosed |
| US-5981533-A | INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR EPIDERMAL GROWTH FACTOR AND CAN BE USED IN THE CASE OF EPIDERMAL HYPERPROLIFERATION (PSORIASIS) AND AS ANTI-TUMOR AGENTS | NOVARTIS AG (CH) | 1999-11-09 | — | — | US | disclosed |
| WO-1998014449-A1 | FUSED PYRAZOLE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
| EP-0819129-A1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031510-A1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | SRC 1332/4885EGFR 3921/4885ABL1 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.